Abciximab in the treatment of acute myocardial infarction eligible for primary percutaneous transluminal coronary angioplasty: Results of the glycoprotein receptor antagonist patency evaluation (GRAPE) pilot study
- 31 May 1999
- journal article
- Published by Elsevier in Journal of the American College of Cardiology
- Vol. 33 (6) , 1528-1532
- https://doi.org/10.1016/s0735-1097(99)00038-8
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Inhibition of the Platelet Glycoprotein IIb/IIIa Receptor with Tirofiban in Unstable Angina and Non–Q-Wave Myocardial InfarctionNew England Journal of Medicine, 1998
- High Dose Bolus Heparin as Initial Therapy Before Primary Angioplasty for Acute Myocardial Infarction: Results of the Heparin in Early Patency (HEAP) Pilot StudyJournal of the American College of Cardiology, 1998
- Confirmation that heparin is an alternative means of promoting early reperfusionCoronary Artery Disease, 1998
- Comparison of Primary Coronary Angioplasty and Intravenous Thrombolytic Therapy for Acute Myocardial InfarctionJAMA, 1997
- Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE studyThe Lancet, 1997
- An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial InfarctionNew England Journal of Medicine, 1993
- A Comparison of Immediate Coronary Angioplasty with Intravenous Streptokinase in Acute Myocardial InfarctionNew England Journal of Medicine, 1993
- A Comparison of Immediate Angioplasty with Thrombolytic Therapy for Acute Myocardial InfarctionNew England Journal of Medicine, 1993
- Comparison of Invasive and Conservative Strategies after Treatment with Intravenous Tissue Plasminogen Activator in Acute Myocardial InfarctionNew England Journal of Medicine, 1989
- IMPROVED SURVIVAL AFTER EARLY THROMBOLYSIS IN ACUTE MYOCARDIAL INFARCTIONThe Lancet, 1985